CCS AI Platform Enhances CGM Adherence, Saves Over $10M in Medicare Diabetes Care
CCS’s AI-driven PropheSee™ platform significantly improves CGM adherence in Medicare diabetes patients, saving $10M+ and advancing preventive chronic care.
Novo Nordisk Seeks FDA Approval for Oral Anti-Obesity Drug Amid GLP-1 Market Competition
Novo Nordisk applies for FDA approval of oral anti-obesity drug following Eli Lilly's clinical success, intensifying competition in the GLP-1 diabetes and weight loss market.
Medicare Coverage and Costs for Diabetes Medications Including Metformin
Explore how Medicare covers diabetes treatments and costs including Metformin and other diabetic supplies under Parts A, B, C, and D. Understand cost factors like premiums and deductibles.
High Discontinuation Rates for Weight Loss Drugs Due to Cost
A study finds that nearly 65% of users of weight loss drugs like Ozempic quit due to high costs and limited insurance coverage. Understanding the challenges in affordability and access is crucial to improve health outcomes.
Medicare Expands Access to Continuous Glucose Monitors for Seniors
Recent Medicare changes now allow more seniors to access continuous glucose monitors, improving diabetes management at low cost.